FDA Releases Draft Guidance on Surgical Robots
核心洞察
The FDA released a 50-page draft guidance outlining what it expects in premarket submissions for robotically assisted surgical devices.
The document covers system stability and latency, instrument motion and position control, visualization, software, wireless technology, cybersecurity, sterilization, labeling and training.
The agency will hold a two-day public workshop on Dec. 2-3 on evaluating benefits and risks of robotic devices with autonomous or remote teleoperation capabilities.
The FDA has released a draft guidance document specifying what the agency wants to see in premarket submissions for robotically assisted surgical devices. The 50-page document details criteria across system stability and latency, instrument motion and position control, visualization, software, wireless technology, cybersecurity, sterilization, labeling and training.
The agency defines surgical robots as teleoperated, software-controlled systems with technologies and subassemblies designed to assist clinicians in using instruments for open, minimally invasive or endoluminal procedures, and notes that robotic technologies may contain some level of automated functions. The FDA also said it will hold a two-day public workshop on Dec. 2-3 focused on evaluating the benefits and risks of robotic medical devices with autonomous or remote teleoperation capabilities, a signal that telesurgery is on the agency's radar as more remote procedures are performed globally.
The draft guidance arrives as a steady stream of new robotic surgery systems enters the marketplace, many competing with longtime leader Intuitive (搜索). Evercore ISI analysts wrote in a research note that the document is a positive for the industry because it lays out a specific approval pathway compared with a prior framework that had some ambiguity, noting that software and cybersecurity in particular can become hurdles without a standardized framework. They added that it helps companies planning newer versions of existing systems by detailing how to show substantial equivalence to predicate devices, and that it provides clarity on clinical endpoints for different procedures plus a pathway for umbrella procedure approval covering a more complex procedure within the same category.